During the COVID-19 pandemic, a period of unprecedented uncertainty and disruption, one of the leading biopharmaceutical companies wanted to develop an Integrated Evidence Generation Plan (IEGP) to identify the critical evidence gaps & corresponding studies/initiatives that advance the COVID-19 portfolio’s priorities and Real-World Evidence (RWE) needs. We were selected as the preferred partner following a competitive bidding process due to our proven expertise, honed from collaborations with many of the top 20 biopharmaceutical companies on medical strategy and integrated evidence-generation plans in both global and regional contexts. Princeton Biopartners helped the client identify actionable evidence initiatives, successfully contributing to >$15B in annual sales.
Challenges
- Dynamic Pandemic Environment: In 2020, the company navigated a rapidly evolving landscape, with over 50% of research efforts redirected towards COVID-19, necessitating constant adaptation to shifting health priorities and regulatory changes.
- Challenging Stakeholder Alignment: Both internal teams and external partners experienced diverging views on priorities, leading to fragmented communications and alignment challenges during critical decision-making moments.
- Rapid Organizational Scale-Up: Amid a period of rapid expansion, the introduction of new functions and departments occurred with limited cross-functional collaboration, resulting in isolated operations during a critical phase of growth.
- Competitive Market Pressure: Entering a fiercely competitive market at launch, the company faced intense pressure to maintain a leading edge, demanding agile strategies and precise execution to stay ahead.
Approach
To deliver a robust evidence-generation strategy, our team designed a high-level project framework:
Discovery
- Knowledge Book: Conducted a comprehensive data audit and landscape analysis to map both internal and external information sources.
- Evidence Landscape Audit: Conducted a robust primary and secondary research initiative, combining internal data, competitor analysis, and literature reviews.
- AI-Powered Gap Identification: Leveraged Evexa’s AI engine to synthesize large volumes of data and feedback, identifying underexplored gaps across the vaccine lifecycle.
- Stakeholder Interviews & Validation: Conducted targeted interviews with cross-functional leaders to validate findings and incorporate on-the-ground perspectives from affiliates.
Design
- Summit Workshop: Organised a multi-day summit to collaboratively review, prioritize, and brainstorm initiatives addressing the identified data gaps.
- Concept validation: Refined and validated proposed initiatives through targeted primary research, ensuring alignment with strategic goals.
Implementation
- Digital Rollout: Deployed the strategy via the Evexa digital platform that supports rapid updates and fosters seamless cross-team communication.
- Quarterly Updates: Developed succinct quarterly decks to keep leadership informed and track progress on addressing key data gaps.
Impact
Our recommendations enabled the client to identify and prioritize key data gaps, translating these insights into actionable evidence initiatives that aligned seamlessly with their strategic priorities. Our approach began with a hands-on discovery phase, followed by successful cross-functional workshops that generated clear, actionable improvement opportunities.
Key impact areas included:
- Data Gap Identification: A rigorous discovery process audited internal and external data, pinpointing areas of strength and deficiency to establish a clear roadmap for targeted action.
- Cross-functional Alignment: Engaging regional and departmental stakeholders ensured diverse perspectives were captured, leading to a unified approach in prioritizing evidence needs.
- Actionable Initiatives: Collaborative workshops led to the development of targeted initiatives that accelerated the education of healthcare professionals (HCPs) on vaccine value, fostering a more agile market response.
These efforts contributed to a 2,200%+ growth in vaccine uptake and a 25–30% share of the market for the client represented.
Expertise Utilised
- Evidence Gap Discovery & Prioritization We apply structured methodologies — including primary and secondary research, internal data audits, and stakeholder synthesis — to uncover, validate, and prioritize evidence gaps that matter most to strategic decision-making.
- Cross-Functional Workshop Design & Facilitation Our team designs and facilitates high-impact workshops that bring together RWE, HEOR, medical, and commercial teams to co-create actionable initiatives and build internal alignment.
- Digital IEGP Enablement (via Evexa) Through our proprietary platform, Evexa, we digitize evidence strategies, enabling dynamic updates, transparent tracking, and cross-regional coordination at scale.
- Integrated Evidence Planning Methodology Our proprietary IEGP framework ensures that evidence initiatives are tightly aligned with asset, portfolio, and organizational goals — supporting both immediate needs and long-term strategic positioning.
- Stakeholder Insight Integration We bring structure to feedback — combining KOL input, internal interviews, and cross-functional touchpoints — to ensure evidence strategies reflect diverse perspectives and drive internal buy-in.
Contact us to learn how we can drive sustainable improvements for your organization.